NCT01412671View on ClinicalTrials.gov

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

CompletedOBSERVATIONAL

Enrollment

117

Participants

Timeline

Start Date

February 27, 2008

Primary Completion Date

September 21, 2011

Study Completion Date

February 28, 2016

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients who have received Nexavar for unresectable or advanced RCC.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY